These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 22147714)

  • 1. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
    Nayak S; Roberts MS; Greenspan SL
    Ann Intern Med; 2011 Dec; 155(11):751-61. PubMed ID: 22147714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Virtual Bone Strength Testing in Osteoporosis Screening Programs for Postmenopausal Women in the United States.
    Agten CA; Ramme AJ; Kang S; Honig S; Chang G
    Radiology; 2017 Nov; 285(2):506-517. PubMed ID: 28613988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.
    Si L; Winzenberg TM; Chen M; Jiang Q; Neil A; Palmer AJ
    Osteoporos Int; 2016 Jul; 27(7):2259-2269. PubMed ID: 26815042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.
    Ito K; Leslie WD
    Osteoporos Int; 2015 Aug; 26(8):2111-9. PubMed ID: 25807913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
    Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
    Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?
    Yang J; Cosman F; Stone PW; Li M; Nieves JW
    Osteoporos Int; 2020 Dec; 31(12):2321-2335. PubMed ID: 32778935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis.
    Marín F; López-Bastida J; Díez-Pérez A; Sacristán JA;
    Calcif Tissue Int; 2004 Mar; 74(3):277-83. PubMed ID: 14708042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
    Ito K
    JAMA Netw Open; 2020 Dec; 3(12):e2027584. PubMed ID: 33258906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
    Schwenkglenks M; Lippuner K
    Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
    Mueller D; Gandjour A
    Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
    Nayak S; Roberts MS; Greenspan SL
    PLoS One; 2012; 7(3):e32879. PubMed ID: 22427903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.